Literature DB >> 31100224

Features and Prognostic Significance of Intraductal Carcinoma of the Prostate.

Rodolfo Montironi1, Ming Zhou2, Cristina Magi-Galluzzi3, Jonathan I Epstein4.   

Abstract

CONTEXT: Intraductal carcinoma of the prostate (IDC-P) is an intraglandular/ductal neoplastic growth of glandular epithelial cells characterized by marked abnormality of the glandular architecture and/or cytological atypia that exceeds what is typically seen in high-grade prostatic intraepithelial neoplasia (HPGIN). It has been shown that IDC-P is a strong independent indicator of poor prognosis for prostate carcinoma (PCa).
OBJECTIVE: To review the pathological and genetic features, diagnostic criteria and differential diagnosis, and clinical significance of IDC-P. EVIDENCE ACQUISITION: PubMed was searched using keywords including prostate carcinoma, intraductal carcinoma, IDC, histology, diagnostic criteria, and prognosis. The references in relevant articles were also reviewed. EVIDENCE SYNTHESIS: IDC-P is a distinct entity with characteristic morphological and genetic features. It is strongly associated with aggressive PCa with high Gleason score/grade groups and large tumor volume, and portends unfavorable clinical outcomes. Morphological diagnostic criteria have been established to distinguish it from other lesions with similar histological features. IDC-P is an uncommon finding in prostate biopsies, and is even rarer as an isolated finding without concomitant PCa. However, patients with isolated IDC-P in biopsy specimens are recommended to have either definitive treatment or immediate repeat biopsy.
CONCLUSIONS: It is critical to recognize and report IDC-P, especially in prostate biopsies, where the clinical impact of such a diagnosis is greatest. PATIENT
SUMMARY: Intraductal carcinoma is a unique form of aggressive prostate cancer. In this report, we review its pathological and genetic features and poor prognostic significance. It is critical for pathologists to recognize and report this lesion in prostate specimens, especially in prostate biopsies for patient management.
Copyright © 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Diagnosis; Intraductal carcinoma; Prognosis; Prostate carcinoma

Mesh:

Year:  2018        PMID: 31100224     DOI: 10.1016/j.euo.2018.03.013

Source DB:  PubMed          Journal:  Eur Urol Oncol        ISSN: 2588-9311


  5 in total

Review 1.  Cribriform Patterned Lesions in the Prostate Gland with Emphasis on Differential Diagnosis and Clinical Significance.

Authors:  Maria Destouni; Andreas C Lazaris; Vasiliki Tzelepi
Journal:  Cancers (Basel)       Date:  2022-06-21       Impact factor: 6.575

2.  The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first-line therapy for patients with metastatic castration-resistant prostate cancer.

Authors:  Zhipeng Wang; Sha Zhu; Jinge Zhao; Ling Nie; Xueqin Chen; Mengni Zhang; Ni Chen; Guangxi Sun; Junru Chen; Yuchao Ni; Jindong Dai; Zhenhua Liu; Ronggui Tao; Xingming Zhang; Xudong Zhu; Haoran Zhang; Jiayu Liang; Zilin Wang; Ben He; Pengfei Shen; Hao Zeng
Journal:  Prostate       Date:  2021-08-26       Impact factor: 4.012

Review 3.  Genomic Features and Clinical Implications of Intraductal Carcinoma of the Prostate.

Authors:  Minyong Kang; Hyunwoo Lee; Sun-Ju Byeon; Ghee Young Kwon; Seong Soo Jeon
Journal:  Int J Mol Sci       Date:  2021-12-04       Impact factor: 5.923

4.  Looking for a Simplified Diagnostic Model to Identify Potentially Lethal Cases of Prostate Cancer at Initial Diagnosis: An ImGO Pilot Study.

Authors:  Serena Macrini; Simona Francesconi; Cecilia Caprera; Daniela Lancia; Matteo Corsi; Marco Gunnellini; Andrea Rocchi; Anjuta Pireddu; Fiovo Marziani; Claudia Mosillo; Maria Letizia Calandrella; Claudia Caserta; Diana Giannarelli; Annalisa Guida; Stefano Ascani; Sergio Bracarda
Journal:  Cancers (Basel)       Date:  2022-03-17       Impact factor: 6.639

Review 5.  Current Understanding and Management of Intraductal Carcinoma of the Prostate.

Authors:  Bryden Considine; Adebowale Adeniran; Michael E Hurwitz
Journal:  Curr Oncol Rep       Date:  2021-07-16       Impact factor: 5.075

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.